 Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022 LEXINGTON, Mass., Jan. 23, 2023 GLOBE NEWSWIRE T2 Biosystems, Inc. NASDAQ:TTOO, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year ... The post T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results appeared... 